The company is to install its LIGHT system in a facility on the campus of University Hospitals Birmingham NHS Foundation Trust (UHB).
It’s a fourth significant tie-up for AVO and follows on from agreements with the Cleveland Clinic, The London Clinic and the Mediterranean Hospital of Limassol.
Chief executive Nicolas Serandour said UBH was a leader in the “non-surgical cancer treatment field”.
As such the pair will work together on “various research and development activities…to increase the awareness of proton therapy for the treatment of cancer”.
No commercial details were provided, although AVO confirmed a revenue-sharing arrangement will be implemented.
“The collaboration is aimed at delivering best treatment modalities for patients and further establishes our network of scientific partners, positioning Advanced Oncotherapy at the forefront of clinical innovation,” added CEO Serandour.
“UHB's choice of Advanced Oncotherapy not only strengthens our leading position as technology disruptor in proton therapy, but also demonstrates our strong momentum and the clear opportunity we have to meet a significant unmet medical need.”